EMEA-001672-PIP01-14 - paediatric investigation plan

varicella-zoster virus (live, attenuated)

Key facts

• Invented name:
  • Zostavax
  • Copalia
• Active Substance:
  varicella-zoster virus (live, attenuated)
• Therapeutic area:
  Vaccines
• Decision number:
  P/0309/2014
• PIP number:
  EMEA-001672-PIP01-14
• Pharmaceutical form(s):
  Powder and solvent for suspension for injection
• Route(s) of administration:
  • Subcutaneous use
  • Intramuscular use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  24/11/2014

Decision

P/0309/2014: EMA decision of 24 November 2014 on the granting of a product specific waiver for varicella-zoster virus (live, attenuated) (Zostavax) (EMEA-001672-PIP01-14)

AdoptedReference Number: EMA/624743/2014